Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ATRN-119

PreclinicalSmall molecule

AAprea Therapeutics

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

HPV Positive Oropharyngeal Squamous Cell CarcinomaNot yet recruiting

HPV Positive Oropharyngeal Squamous Cell CarcinomaPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q1 2028

Phase 1/2Active, not recruiting

Patients With Advanced Solid Tumors

NCT04905914

Q3 2030

PreclinicalNot yet recruiting

HPV Positive Oropharyngeal Squamous Cell Carcinoma

NCT07578467

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Study Of ATRN-119 In Patients With Advanced Solid Tumors

Active, not recruiting·AAprea Therapeutics·Phase 1/2·NCT04905914·132 enrolled

HPV Positive Oropharyngeal Squamous Cell Carcinoma1 trial

A Phase Ib/II Study Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs

Not yet recruiting·AAbramson Cancer Center at Penn Medicine·Preclinical·NCT07578467·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ATRN-119. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATRN-119 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATRN-119. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aprea Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAprea Therapeutics

Related News